Literature DB >> 305891

Inhibition of the classical and alternative pathways by amino acids and their derivatives.

Y Takada, Y Arimoto, H Mineda, A Takada.   

Abstract

Effects of various aminoacids and their derivatives on the classical pathway and alternative pathway of the complement were studied. Leupeptin, acetyl-leucyl-leucyl-arginal, inhibited CH50 and Cl-esterase, but did not inhibit the alternative pathway. When aminoacids of carbon chains of the order of seven were used, arginine and lysine had stronger effects than trans-aminomethyl cyclohexane carboxylic acid (t-AMCHA), cis-aminomethyl cyclohexane carboxylic acid (cis-AMCHA) and epsilon aminocaproic acid (EACA). SH-compounds, cysteine, homocysteine and glutathione, had the strongest inhibitory effects among these aminoacids on both classical and alternative pathways. When effects on Cl esterase were compared, arginine, lysine, t-AMCHA, cis-AMCHA and EACA had weak inhibition while SH-compounds showed strong inhibition. Poly-L-lysine, which had extremely strong inhibition of CH50, had no inhibition of Cl esterase. The inhibitory effects of antifibrinolytic agents, EACA and t-AMCHA, were weak but when effects on early parts of the classical pathway, C(1,4,2)H50 were tested, some inhibitory activities were recognized. Thus inhibitory effects of these agents were due to their activities on the early parts of the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305891      PMCID: PMC1457603     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  INHIBITION OF THE C'-1 COMPONENT OF COMPLEMENT BY AMINO ACIDS.

Authors:  F B TAYLOR; H FUDENBERG
Journal:  Immunology       Date:  1964-07       Impact factor: 7.397

2.  STUDIES ON HUMAN C'1-ESTERASE. I. PURIFICATION AND ENZYMATIC PROPERTIES.

Authors:  A L HAINES; I H LEPOW
Journal:  J Immunol       Date:  1964-03       Impact factor: 5.422

3.  CHROMATOGRAPHIC SEPARATION OF THE FIRST COMPONENT OF COMPLEMENT AND ITS ASSAY ON A MOLECULAR BASIS.

Authors:  T BORSOS; H J RAPP
Journal:  J Immunol       Date:  1963-12       Impact factor: 5.422

4.  AN ACTIVE STEREO-ISOMER (TRANS-FORM) OF AMCHA AND ITS ANTIFIBRINOLYTIC (ANTIPLASMINIC) ACTION IN VITRO AND IN VIVO.

Authors:  S OKAMOTO; S SATO; Y TAKADA; U OKAMOTO
Journal:  Keio J Med       Date:  1964-12

5.  Measurement of the rate of plasmin action on synthetic substrates.

Authors:  P S ROBERTS
Journal:  J Biol Chem       Date:  1958-05       Impact factor: 5.157

6.  Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions.

Authors:  M Loos; J E Volanakis; R M Stroud
Journal:  Immunochemistry       Date:  1976-09

7.  Activation of the alternate pathway of human complements by rabbit cells.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

8.  Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.

Authors:  V Brade; A Nicholson; D Bitter-Suermann; U Hadding
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

9.  C1 inactivator inhibition by plasmin.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

10.  Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator.

Authors:  E H Vallota; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1973-05-01       Impact factor: 14.307

View more
  11 in total

1.  Complement, complement activation and anaphylatoxins in human ovarian follicular fluid.

Authors:  R Perricone; C de Carolis; C Moretti; E Santuari; G de Sanctis; L Fontana
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Chronic gastrointestinal haemorrhage controlled by antifibrinolytic agents.

Authors:  J M Willoughby
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

3.  Relationships between the haemolytic activities of the human complement system and complement components.

Authors:  A Takada; Y Imamura; Y Takada
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

4.  Inhibition of immune complex-mediated activation of complement. Effects of agents modulating activation of, and the activated C1 complex.

Authors:  D S Fletcher; T Y Lin
Journal:  Inflammation       Date:  1980-03       Impact factor: 4.092

5.  In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA).

Authors:  M Etievant; B Leluc; B David
Journal:  Agents Actions       Date:  1988-06

6.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

7.  The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

8.  Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B.

Authors:  C W Clardy
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  The inhibition by lysine of the activation of the first component of complement, C1.

Authors:  A Takada; Y Takada
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

10.  Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS).

Authors:  R Perricone; L Fontana; C de Carolis; C Carini; M C Sirianni; F Aiuti
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.